Advertisement

World Journal of Surgery

, Volume 41, Issue 3, pp 825–834 | Cite as

Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

  • Dong-Hwan Jung
  • Shin HwangEmail author
  • Ki-Hun Kim
  • Seung-Mo Hong
  • Young-Joo Lee
  • Chul-Soo Ahn
  • Deok-Bog Moon
  • Tae-Yong Ha
  • Gi-Won Song
  • Gil-Chun Park
  • Eun Sil Yu
  • Sung-Gyu Lee
Original Scientific Report

Abstract

Background

Simultaneous double primary hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) (dpHCC-ICC) is very rare. This study investigated the clinicopathological features and post-resection prognosis of dpHCC-ICC.

Methods

We identified 10 patients with dpHCC-ICC through an institutional database search. Three control groups with HCC, ICC and combined HCC-cholangiocarcinoma (cHCC-CC) were selected (each n = 120) using propensity score matching.

Results

The incidence of dpHCC-ICC was 0.23%. The mean age was 57.4 ± 11.7 years, and 8 were male. Hepatitis B virus infection was associated with 8 patients. All dpHCC-ICC were diagnosed incidentally from surgical specimens. Only two patients demonstrated simultaneous elevation of alpha-fetoprotein/des-γ-carboxy prothrombin and carbohydrate antigen 19-9. All patients underwent macroscopic curative resection. The HCC component was classified as stage I in 7 and stage II in 3, and ICC component was classified as stage I in 5, stage II in 2 and stage IV in 3. Tumor recurrence and patient survival rates were 30.0 and 90.0% at 1 year and 52.0 and 77.1% at 3 years, respectively. Tumor recurrence rates were not different between the dpHCC-ICC and the three control groups (p = 0.505). The overall and post-recurrence patient survival rates were similar between the dpHCC-ICC and cHCC-CC groups (p > 0.2); however, these were inferior to those in the HCC group but comparable with those in the ICC group.

Conclusions

The post-resection prognosis of dpHCC-ICC was more dependent on the tumor stage of the ICC component than that of the HCC component. Therefore, they can be clinically regarded as ICC with concurrent HCC.

Keywords

Primary Liver Cancer Intrahepatic Cholangiocarcinoma Hepatic Progenitor Cell Tumor Recurrence Rate Primary Liver Malignancy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (Grant No. 2015R1A2A2A04007141 to Hwang S).

Author contributions

SH and DHJ designed the study; KHK, SMH, YJL, CSA, DBM, HT-Y, SG-W, ESY and SGL contributed to the data acquisition and analysis; and SH and DHJ drafted and revised the article. All authors have approved the submitted version of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to disclose.

References

  1. 1.
    Allen RA, Lisa JR (1949) Combined liver cell and bile duct carcinoma. Am J Pathol 25:647–655PubMedPubMedCentralGoogle Scholar
  2. 2.
    Theise ND, Park YN, Nakanuma Y (2010) Combined hepatocellular-cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumours of the digestive system, 4th edn. IARC, Lyon, pp 225–227Google Scholar
  3. 3.
    Zhang F, Chen XP, Zhang W et al (2008) Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology 52:224–232CrossRefPubMedGoogle Scholar
  4. 4.
    Cao J, Huang L, Liu C et al (2013) Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) in a single patient: a clinicopathologic study of 35 resected cases. J Gastroenterol Hepatol 28:1025–1031CrossRefPubMedGoogle Scholar
  5. 5.
    Yoshikawa T, Hirota S, Matsumoto S et al (2001) Double cancer, cholangiocellular and hepatocellular carcinomas, in the cirrhotic liver. Radiat Med 20:33–36Google Scholar
  6. 6.
    Inaba K, Suzuki S, Sakaguchi T et al (2007) Double primary liver cancer (intrahepatic cholangiocarcinoma and hepatocellular carcinoma) in a patient with hepatitis C virus-related cirrhosis. J Hepatobiliary Pancreat Surg 14:204–209CrossRefPubMedGoogle Scholar
  7. 7.
    Matsuda M, Hara M, Suzuki T et al (2006) Synchronously resected double primary hepatic cancers—hepatocellular carcinoma and cholangiolocellular carcinoma. J Hepatobiliary Pancreat Surg 13:571–576CrossRefPubMedGoogle Scholar
  8. 8.
    Hwang S, Lee YJ, Kim KH et al (2015) The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2558 patients. J Gastrointest Surg 19:1281–1290CrossRefPubMedGoogle Scholar
  9. 9.
    Hwang S, Lee YJ, Song GW et al (2015) Prognostic impact of tumor growth type on 7th AJCC staging system for intrahepatic cholangiocarcinoma: a single-center experience of 659 cases. J Gastrointest Surg 19:1291–1304CrossRefPubMedGoogle Scholar
  10. 10.
    Yoon YI, Hwang S, Lee YJ et al (2016) Postresection outcomes of combined hepatocellular carcinoma-cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Gastrointest Surg 20:411–420CrossRefPubMedGoogle Scholar
  11. 11.
    Cho HD, Hwang S, Lee YJ et al (2016) Changes in the types of liver diseases requiring hepatic resection: a single-institution experience of 9016 cases over a 10-year period. Korean J Hepatobiliary Pancreat Surg 20:49–52CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hwang S, Ha TY, Song GW et al (2015) Quantified risk assessment for major hepatectomy via the indocyanine green clearance rate and liver volumetry combined with standard liver volume. J Gastrointest Surg 19:1305–1314CrossRefPubMedGoogle Scholar
  13. 13.
    The Korean Association for the Study of the Liver (KASL) (2016) KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 22:18–75CrossRefGoogle Scholar
  14. 14.
    Garancini M, Goffredo P, Pagni F et al (2014) Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transplant 20:952–959CrossRefGoogle Scholar
  15. 15.
    Fowler K, Saad NE, Brunt E et al (2015) Biphenotypic primary liver carcinomas: assessing outcomes of hepatic directed therapy. Ann Surg Oncol 22:4130–4137CrossRefPubMedGoogle Scholar
  16. 16.
    Wu CY, Lin JT, Ho HJ et al (2014) Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-A nationwide cohort study. Gastroenterology 147(143–151):e5Google Scholar
  17. 17.
    Tarocchi M, Polvani S, Marroncini G et al (2014) Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol 20:11630–11640CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Lee CH, Chang CJ, Lin YJ et al (2009) Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer 100:1765–1770CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Wu ZF, Wu XY, Zhu N et al (2015) Prognosis after resection for hepatitis B virus-associated intrahepatic cholangiocarcinoma. World J Gastroenterol 21:935–943CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ralphs S, Khan SA (2013) The role of the hepatitis viruses in cholangiocarcinoma. J Viral Hepat 20:297–305CrossRefPubMedGoogle Scholar
  21. 21.
    Fwu CW, Chien YC, You SL et al (2011) Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan. Hepatology 53:1217–1225CrossRefPubMedGoogle Scholar
  22. 22.
    Lee TY, Lee SS, Jung SW et al (2008) Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol 103:1716–1720CrossRefPubMedGoogle Scholar
  23. 23.
    Li M, Li J, Li P et al (2012) Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J Gastroenterol Hepatol 27:1561–1568CrossRefPubMedGoogle Scholar
  24. 24.
    Zhou Y, Zhao Y, Li B et al (2012) Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer 12:289CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Palmer WC, Patel T (2012) Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 57:69–76CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Akiba J, Nakashima O, Hattori S et al (2013) Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 37:496–505CrossRefPubMedGoogle Scholar
  27. 27.
    Chu KJ, Lu CD, Dong H et al (2014) Hepatitis B virus-related combined hepatocellular-cholangiocarcinoma: clinicopathological and prognostic analysis of 390 cases. Eur J Gastroenterol Hepatol 26:192–199CrossRefPubMedGoogle Scholar
  28. 28.
    Wu CY, Lin JT, Ho HJ et al (2014) Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-A nationwide cohort study. Gastroenterology 147:143–151CrossRefPubMedGoogle Scholar
  29. 29.
    Hosaka T, Suzuki F, Kobayashi M et al (2013) Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58:98–107CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2016

Authors and Affiliations

  • Dong-Hwan Jung
    • 1
  • Shin Hwang
    • 1
    Email author
  • Ki-Hun Kim
    • 1
  • Seung-Mo Hong
    • 2
  • Young-Joo Lee
    • 1
  • Chul-Soo Ahn
    • 1
  • Deok-Bog Moon
    • 1
  • Tae-Yong Ha
    • 1
  • Gi-Won Song
    • 1
  • Gil-Chun Park
    • 1
  • Eun Sil Yu
    • 2
  • Sung-Gyu Lee
    • 1
  1. 1.Department of Surgery, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea
  2. 2.Department of Pathology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea

Personalised recommendations